

**RECONCILIATION OF SHARE CAPITAL AUDIT FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE, 2022**  
(Regulation 76 of SEBI (Depository and Participant) Regulations, 2018)

1.	For the quarter ended	30th June, 2022					
2.	ISIN	INE03QK01018					
3.	Face Value	Re. 1.00/- each					
4.	Name of the Company	SUVEN PHARMACEUTICALS LIMITED					
5.	Registered Office Address	# 8-2-334, SDE Serene Chambers 3rd Floor, Avenue 7, Road No. 5 Banjara Hills, Hyderabad – 500 034					
6.	Correspondence Address	Same as above					
7.	Telephone & Fax No.	Ph: 040 – 23549414/3311 Fax 040 – 23541152					
8.	Email Address	<a href="mailto:khrao@suvanpharm.com">khrao@suvanpharm.com</a>					
9.	Names of the Stock exchanges where the Company's Securities are listed.	BSE Limited National Stock Exchange of India Ltd					
		Number of shares			% of Total Issued Capital		
10.	Issued Capital	25,45,64,956			100.00		
11.	Listed Capital (exchange wise) (as per Company Records)	25,45,64,956–NSE 25,45,64,956–BSE			100.00 100.00		
12.	Held in dematerialized form in CDSL	1,43,58,083			5.64%		
13.	Held in dematerialized form in NSDL	23,95,45,080			94.10%		
14.	Physical	6,61,793			0.26%		
15.	Total No. of shares (12+13+14)	25,45,64,956			100.00%		
16.	Reasons for difference if any between (10&11, 10& 15, 11 & 15)				NIL		
17.	Certifying the details of changes in sharecapital during the quarter under consideration as per Table Below						
	Particulars*	No. of Shares	Applied or not applied for listing	Listed on Exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Approval pending for stock exchange (Specify names)
	NIL	NIL	NIL	NIL	NIL	NIL	NIL


\*Rights, Bonus, Pref. Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital reduction, forfeiture, any other (Specify)

**OFFICE :**

Plot No. 143, Flat No. 301, SV's Kausalya Complex, Rajeev Nagar, Hyderabad - 45.



18.	Register of members electronically updated (Y/N)	Yes		
19.	Reference of previous quarter with regards to excess dematerialized shares, if any	Nil		
20.	Has the Company resolved the matter mentioned in point No. 19 above in the current quarter? If not, reason, why?	Not applicable		
21.	Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with reasons for delay.	Nil		
Total No. of dematrequests		No. of requests	No. of shares	Reasons for delay
Confirmed after 21 days		Nil	Nil	Nil
Pending for more than 21 days		Nil	Nil	Nil
22.	Name, Telephone & Fax No. of Compliance Officer of the Company	K.Hanumantha Rao Ph: 040 – 23549414/3311 Fax 040 – 23541152		
23.	Name, Address, Tel. & Fax No., Reg. No. of Auditor of the Company	CS. D. Renuka Practicing Company Secretary Plot No. 143, Flat No. 301, S V Kausalya Complex, Rajeev Nagar, Hyderabad - 500045 Mobile: +91-98480 59315 Reg. No: ACS11963		
24.	Appointment of Common agency for share registry work, if yes (name and address)	KFin Technologies Limited Selenium Tower B, Plot 31-32 Gachibowli, Financial District Nanakramguda, Hyderabad – 500032		
25.	Any other detail that the auditor may like to provide (e.g. BIFR Company, delisting from S.E, Company changed its name etc.)	NIL		



D. RENUKA  
Company Secretary in Practice  
C. P. No. 3460

ICSI Peer Review UIN :L2000TL172900  
UDIN: A011963D000615830

Place: Hyderabad  
Date: July 13, 2022